EP
HZNP

Eversept Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Eversept Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-70,000
Closed -$7.54M – 118
2021
Q4 		$7.54M Hold
70,000
– – 0.48% 53
2021
Q3 		$7.67M Hold
70,000
– – 0.53% 47
2021
Q2 		$6.55M Buy
+70,000
New +$6.44M 0.44% 43

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Eversept Partners's HZNP Position: Q4 2023 in Review

Eversept Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 205,815 shares — an estimated $23.8M sold.

Eversept Partners first reported a position in HZNP in Q2 2020 and held it in 14 quarters. The position peaked at $121M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Eversept Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Eversept Partners sold 205,815 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $23.8M.
  • Eversept Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 14 quarters.
  • Eversept Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $121M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Eversept Partners's 13F filing for Q4 2023, filed 14 Feb 2024.